Breast cancer treatment typically involves a combination of surgery, radiation, and systemic therapies like hormone-blocking drugs, chemotherapy, or targeted medicines. The specific plan depends on the cancer’s stage, its molecular subtype, and whether it has spread beyond the breast. When caught early and confined to the breast, the five-year survival rate is effectively 100%. Even when cancer has spread to nearby lymph nodes, that number is 87.5%.
Understanding your subtype and stage is the foundation for every treatment decision that follows. Here’s what each part of treatment looks like and how the pieces fit together.
Why Your Cancer’s Subtype Matters
Not all breast cancers behave the same way. A pathologist tests your tumor for two key features: whether it has hormone receptors (meaning estrogen or progesterone fuel its growth) and whether it overproduces a protein called HER2 that drives rapid cell division. These results place your cancer into one of three major categories, and each one is treated differently.
Hormone receptor-positive (HR+) cancers are the most common type. Because these tumors depend on estrogen to grow, the cornerstone of treatment is hormone-blocking therapy, often for five to ten years after surgery. Some HR+ cancers that divide more aggressively also respond well to drugs that interrupt the cell division cycle.
HER2-positive cancers produce excess HER2 protein, making them fast-growing but also highly targetable. Treatment centers on anti-HER2 drugs that bind to the protein and shut down its growth signal, usually combined with chemotherapy. In December 2025, the FDA approved a new first-line combination of two HER2-targeting agents for metastatic HER2-positive breast cancer, expanding options for this subtype.
Triple-negative breast cancer (TNBC) lacks hormone receptors and HER2, which means it doesn’t respond to hormone therapy or standard targeted drugs. Chemotherapy has traditionally been the primary systemic treatment. However, immunotherapy has changed the picture for many patients. In tumors that express a specific immune marker called PD-L1, adding immunotherapy to chemotherapy extended median survival from about 16 months to 23 months in advanced disease. For early-stage TNBC, immunotherapy given before and after surgery also improves outcomes.
Surgery: Lumpectomy vs. Mastectomy
Surgery removes the cancer from the breast and is part of treatment for nearly all early-stage patients. The two main options are lumpectomy (removing the tumor and a margin of surrounding tissue) and mastectomy (removing the entire breast).
For stage I and stage II cancers, clinical trials have shown that lumpectomy followed by radiation produces survival rates equivalent to mastectomy. In fact, a large study tracking over 3,400 women found that those who had lumpectomy with radiation had slightly better ten-year overall survival across all subtypes. Ten-year survival after lumpectomy was 95.2% for the most common hormone-driven subtype and 92.1% for triple-negative, compared to 91.2% and 88.4% after mastectomy for those same groups. The difference was most pronounced in stage II hormone receptor-positive cancers that grow more quickly, where lumpectomy patients had roughly 70% lower risk of death compared to mastectomy patients.
Mastectomy is still recommended in certain situations: when the tumor is large relative to the breast, when there are multiple tumors in different areas, or when radiation isn’t an option. Some women with inherited BRCA gene mutations choose bilateral mastectomy (removing both breasts) to sharply reduce the risk of a new cancer developing later.
Radiation Therapy After Surgery
Radiation kills any microscopic cancer cells left behind after surgery. It’s standard after lumpectomy and sometimes recommended after mastectomy if the cancer was large or had spread to lymph nodes.
The most common approach is external beam radiation directed at the whole breast. The traditional schedule was daily sessions, five days a week, for five to six weeks. Newer shortened courses can now deliver the same treatment in one to four weeks, making the process far more manageable. For some early-stage cancers, partial-breast radiation targets only the area where the tumor was removed, and this can be completed in five days or less.
Hormone Therapy for HR-Positive Cancers
About two-thirds of breast cancers are fueled by hormones, and blocking that fuel supply is one of the most effective long-term treatments available. These medications are taken daily as pills, usually for five to ten years after surgery, to reduce the risk of the cancer returning.
For women who haven’t gone through menopause, the standard drug blocks estrogen from attaching to cancer cells, essentially cutting off the growth signal. For postmenopausal women, a different class of drugs called aromatase inhibitors works by stopping the body from producing estrogen in the first place. Premenopausal women can also take aromatase inhibitors if combined with ovarian suppression therapy. Some patients take one type for several years and then switch to the other, stretching the total course to a full decade.
How Genetic Testing Changes the Plan
Testing for inherited mutations in the BRCA1 and BRCA2 genes can significantly alter both treatment and prevention strategies. These genes normally help repair damaged DNA. When they’re not working properly, cancer cells lose a key repair mechanism, which actually creates a therapeutic opportunity.
Drugs called PARP inhibitors exploit this weakness. They block another DNA repair pathway, leaving BRCA-mutated cancer cells unable to fix themselves. Four PARP inhibitors are currently FDA-approved for cancers with BRCA mutations. Beyond treating existing cancer, a positive BRCA test also opens conversations about preventive surgery. Some women choose bilateral mastectomy to reduce future breast cancer risk, while removal of the ovaries and fallopian tubes can lower the risk of both ovarian and possibly breast cancer.
Newer Targeted Therapies
The treatment landscape continues to expand, particularly for cancers that have stopped responding to earlier lines of therapy. A new class of drugs called antibody-drug conjugates works like a guided missile: an antibody seeks out a specific protein on cancer cells and delivers a potent chemotherapy payload directly to the tumor, sparing more healthy tissue.
In January 2025, the FDA approved a new antibody-drug conjugate for HR-positive, HER2-negative metastatic breast cancer in patients whose disease has progressed through prior hormone therapy and chemotherapy. These approvals are giving patients with advanced disease treatment options that didn’t exist a few years ago.
What Treatment Side Effects Feel Like
Chemotherapy’s most common short-term side effects include hair loss, fatigue, nausea, loss of appetite, and increased vulnerability to infections because of lowered white blood cell counts. Some people experience nerve tingling or numbness in the hands and feet, and many notice difficulty with memory and concentration, sometimes called “chemo brain.” Most of these resolve after treatment ends, though nerve symptoms can linger.
The longer-term concern with certain chemotherapy drugs is infertility. These drugs can damage the ovaries and trigger early menopause. If future fertility matters to you, preserving eggs or embryos before starting treatment is the time-sensitive step to discuss early. Planning ahead for the practical side of treatment also helps: arranging time off work, lining up help at home for the days after each infusion, and considering a wig or head covering if your regimen is likely to cause hair loss.
Hormone therapy side effects tend to be milder but last years. They often mimic menopause: hot flashes, joint stiffness, mood changes, and vaginal dryness. Radiation typically causes skin irritation and fatigue in the treated area, with symptoms building gradually over the course of treatment and fading in the weeks after.
Reconstruction After Mastectomy
Breast reconstruction can happen at the same time as mastectomy (immediate reconstruction) or weeks to years later (delayed reconstruction). The timing depends on the cancer stage, whether radiation will follow surgery, and personal preference.
Immediate reconstruction generally produces better cosmetic results, involves fewer total surgeries, and reduces the emotional impact of losing a breast. It doesn’t affect the ability to detect cancer recurrence or delay other cancer treatments. The tradeoff is a longer initial surgery and recovery period.
Delayed reconstruction gives you more time to weigh your options, and it avoids potential complications if radiation is needed after mastectomy, since radiation can damage reconstructed tissue. The downside is that scarring from the mastectomy can make reconstruction more challenging and cosmetic results may not be as favorable. Not everyone chooses reconstruction at all, and that’s an equally valid decision.
Survival by Stage
Stage at diagnosis is the single biggest predictor of outcome. Based on the most recent national data, the five-year relative survival rates tell a clear story. Localized breast cancer, meaning the cancer hasn’t spread beyond the breast, has a 100% five-year survival rate. Regional disease, where cancer has reached nearby lymph nodes, drops to 87.5%. Distant or metastatic breast cancer, where cells have spread to other organs, has a five-year survival rate of 33.8%, though newer targeted therapies and immunotherapy are gradually improving this number for specific subtypes.